Highlights: • 83 lymph node dissections following neoadjuvant immunotherapy for stage III metastatic melanoma were assessed. • There was strong reproducibility in assessment of INMC pathologic response category and percentage of viable melanoma. • High fibrosis was associated with a lack of recurrence and increased RFS, representing a possible biomarker. • Two different scoring systems of response were assessed and both scoring systems correlated with a lack of recurrence.
